The Burrill Report (July 12, 2010): Will Investors Hang on to Biotech (.MP3,10.89 Mb)

As 2010 took shape, the worst seemed to be behind us and the year was looking as if it would be a good one for the biotech sector. Lately, though, things seem to turned a tad sour. A downturn in the general market and growing concerns among investors have weighed heavily on the industry. The good news is that companies have been successful at raising money. But while a dozen companies have managed to go public since last summer, their performance has been disappointing and investors’ seem to have little appetite for biotech IPOs. As The Burrill Report gets ready to release it July issue with wrap-up of the first half of the year, we spoke to Editor Peter Winter about what’s happened during 2010, the dealmaking activity to date, and what’s its going to take to kick-start the industry in the second half of the year.